Study Summary
The is a multicenter, single arm, open label clinical study on the novel CAR-T combined expression of IL-15 in the treatment of malignant hematological tumors.Plan to recruit 45 subjects with malignant hematological tumors.
Want to learn more about this trial?
Request More InfoInterventions
chimeric antigen receptor gene modified T cellsDRUG
The rate of intravenous infusion of CAR T cells was 10 mL to 20 mL/min, and the infusion was performed using a blood transfusion apparatus with a filter screen. Use saline rinsing tube prior to infusion; Rinse the infusion bag with 10 mL\~30 mL normal saline.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Shanxi Bethune Hospital | Taiyuan | Shanxi | China |